Antisense-based therapy for the treatment of spinal muscular atrophy

被引：126
作者：
Rigo, Frank [1 ]
Hua, Yimin [2 ]
Krainer, Adrian R. [2 ]
Bennett, C. Frank [1 ]
机构：
[1] ISIS Pharmaceut, Carlsbad, CA 92010 USA
[2] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA
来源：
JOURNAL OF CELL BIOLOGY | 2012年 / 199卷 / 01期
关键词：
EXONIC SPLICING ENHANCER; SURVIVAL-MOTOR-NEURON; CARDIAC DEFECTS; MOUSE MODEL; OLIGONUCLEOTIDE; MECHANISMS; DISEASE; THERAPEUTICS; NECROSIS; MASKING;
D O I：
10.1083/jcb.201207087
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
One of the greatest thrills a biomedical researcher may experience is seeing the product of many years of dedicated effort finally make its way to the patient. As a team, we have worked for the past eight years to discover a drug that could treat a devastating childhood neuromuscular disease, spinal muscular atrophy (SMA). Here, we describe the journey that has led to a promising drug based on the biology underlying the disease.
引用
收藏
页码：21 / 25
页数：5
相关论文
共 37 条
[1]   RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform [J].
Bennett, C. Frank ;
Swayze, Eric E. .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2010, 50 :259-293
[2]   Early heart failure in the SMNΔ7 model of spinal muscular atrophy and correction by postnatal scAAV9-SMN delivery [J].
Bevan, Adam K. ;
Hutchinson, Kirk R. ;
Foust, Kevin D. ;
Braun, Lyndsey ;
McGovern, Vicki L. ;
Schmelzer, Leah ;
Ward, Jennifer G. ;
Petruska, Jeffrey C. ;
Lucchesi, Pamela A. ;
Burghes, Arthur H. M. ;
Kaspar, Brian K. .
HUMAN MOLECULAR GENETICS, 2010, 19 (20) :3895-3905
[3]   Spinal distribution and metabolism of 2′-O-(2-methoxyethyl)-modified oligonucleotides after intrathecal administration in rats [J].
Butler, M ;
Hayes, CS ;
Chappell, A ;
Murray, SF ;
Yaksh, TL ;
Hua, XY .
NEUROSCIENCE, 2005, 131 (03) :705-715
[4]   Correction of disease-associated exon skipping by synthetic exon-specific activators [J].
Cartegni, L ;
Krainer, AR .
NATURE STRUCTURAL BIOLOGY, 2003, 10 (02) :120-125
[5]   Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1 [J].
Cartegni, L ;
Krainer, AR .
NATURE GENETICS, 2002, 30 (04) :377-384
[6]   The neurobiology of childhood spinal muscular atrophy [J].
Crawford, TO ;
Pardo, CA .
NEUROBIOLOGY OF DISEASE, 1996, 3 (02) :97-110
[7]   Vascular Perfusion Abnormalities in Infants with Spinal Muscular Atrophy [J].
de Queiroz Campos Araujo, Alexandra Prufer ;
Araujo, Mario ;
Swoboda, Kathryn J. .
JOURNAL OF PEDIATRICS, 2009, 155 (02) :292-294
[8]   Spinal muscle atrophy type 1 (Werdnig-Hoffman disease) with complex cardiac malformation [J].
El-Matary, W ;
Kotagiri, S ;
Cameron, D ;
Peart, I .
EUROPEAN JOURNAL OF PEDIATRICS, 2004, 163 (06) :331-332
[9]  
Erdine Serdar, 2006, Pain Pract, V6, P51, DOI 10.1111/j.1533-2500.2006.00059.x
[10]   RETRACTED: Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN (Retracted Article) [J].
Foust, Kevin D. ;
Wang, Xueyong ;
McGovern, Vicki L. ;
Braun, Lyndsey ;
Bevan, Adam K. ;
Haidet, Amanda M. ;
Le, Thanh T. ;
Morales, Pablo R. ;
Rich, Mark M. ;
Burghes, Arthur H. M. ;
Kaspar, Brian K. .
NATURE BIOTECHNOLOGY, 2010, 28 (03) :271-U126
1234